Evofem Biosciences Inc (EVFM) USD0.001
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). The Company's product, Phexxi vaginal gel, is an on-demand prescription contraceptive gel for women. Its pipeline product candidate, EVO100 vaginal gel, is evaluated for the prevention of chlamydia trachomatis infection and Neisseria gonorrhoeae in women. The Company also focuses on the development of EVO200 vaginal gel, its candidate for the reduction of recurrent bacterial vaginosis (BV).Its subsidiaries include Evofem Biosciences Operations Inc, Evofem Inc and Evofem Ltd.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.